Dorzagliatin for blood sugar control in type 2 diabetes with kidney disease
Treatments studied
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new oral medication, dorzagliatin, to see if it can improve blood sugar control in people with type 2 diabetes and moderate to severe kidney disease. Participants must be on a stable basal insulin regimen with or without certain oral diabetes drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have type 2 diabetes.
- You must have moderate to severe chronic kidney disease (not on dialysis).
- Your HbA1c (average blood sugar) must be between 7% and 9%.
- You must be on a stable diabetes treatment that includes basal insulin and up to 2 oral medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a new drug called dorzagliatin to see how it affects insulin and other hormones that control blood sugar in people with prediabetes or type 2 diabetes. It may help improve how your body handles sugar.
This study tests if an SGLT2 inhibitor can help protect kidney function in people who have lupus nephritis (kidney inflammation caused by lupus) and chronic kidney disease (CKD). The goal is to see if this medicine can slow down further kidney damage.
This study tests if the drug dorzagliatin can protect kidney function in people with type 2 diabetes who already have mild kidney damage (shown by higher protein in their urine). Participants will be randomly assigned to receive either dorzagliatin or a placebo on top of their usual diabetes medications.
This study tests a drug called dorzagliatin to see if it can help control blood sugar in adults with cystic fibrosis who have pancreatic insufficiency and abnormal glucose tolerance.
This trial tests a new medicine called elecoglipron to see if it helps control blood sugar in people with type 2 diabetes who also have reduced kidney function. You would continue taking your current SGLT2i medication (like dapagliflozin).
This Phase 3 study tests whether LID104 can improve blood sugar control and safety in people with type 2 diabetes who are not meeting their A1c goal on metformin. You may benefit if your diabetes is still too high despite diet, exercise, and the usual metformin dose.
Hear when a new Chronic Kidney Disease (Stages 3b-5) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.